Hydroxyurea mitigates diabetic kidney disease through mTOR-S6K signaling pathway in STZ-induced diabetic mice

Hydroxyurea mitigates diabetic kidney disease through mTOR-S6K signaling pathway in STZ-induced diabetic mice

BackgroundDiabetic kidney disease (DKD) is the leading risk factor for end-stage renal disease (ESRD). Hydroxyurea (HU), a sickle cell disease (SCD) drug approved by FDA, shows protective effect in nephropathy. This study aims to understand whether the application of HU could be effective to treat D...

Full description

Saved in:
Bibliographic Details
Main Authors: Wanying Cheng, Cenzhu Wang, Meican Ma, Yu Zhou
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Cell and Developmental Biology
Subjects:
diabetic kidney disease
hydroxyurea
inflammation
apoptosis
s6k
Online Access:https://www.frontiersin.org/articles/10.3389/fcell.2025.1529901/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items